Trial · NCT07907965
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
NCT07907965, Phase 2, Active not recruiting, Beijing University of Chinese Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease. Trials, record NCT07907965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
- NCT number
- NCT07907965
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Beijing University of Chinese Medicine
- Conditions
- Diabetic Kidney Disease (DKD), Type 2 Diabetes, Albuminuria
- Interventions
- Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen
- First posted
- 2026-10-30
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Urine Albumin-to-Creatinine Ratio (UACR) | Baseline, Week 2, Week 4, Week 8, Week 12, and Week 16 | Urine albumin-to-creatinine ratio (UACR, in mg/g) is measured from spot urine samples collected at six time points: baseline (pre-treatment), and at weeks 2, 4, 8, 12 (end of treatment), and 16 (4 weeks after treatment discontinuation). All samples are analyzed in a central laboratory using standardized assays. The primary analysis focuses on the change in UACR from baseline to week 16. UACR values are compared between groups and within subjects (pre- vs. post-intervention) using appropriate statistical tests. |
| Secondary | Change in Hemoglobin A1c (HbA1c) | baseline and week 12 | Hemoglobin A1c (HbA1c, %) is measured at baseline and week 12 using standardized assays in a central laboratory. The change from baseline to week 12 is analyzed between groups and within subjects (pre- vs. post-intervention). |
| Secondary | Estimated Glomerular Filtration Rate (eGFR) | Baseline, Week 4, Week 8, Week 12, and Week 16 | Estimated glomerular filtration rate (eGFR, mL/min/1.73m²) is calculated from serum creatinine levels at baseline (pre-treatment), and at weeks 4, 8, 12 (end of treatment), and 16 (4 weeks after treatment discontinuation) using the CKD-EPI equation. Changes in eGFR are assessed between groups and within subjects. |
| Secondary | Change in Fasting Plasma Glucose (FPG) | Baseline, Week 4, Week 8, Week 12, and Week 16 | Fasting plasma glucose (FPG, mmol/L) is measured at baseline to week 16. The change from baseline to week 16 is compared between groups and within individuals using appropriate statistical tests. |
| Secondary | Change in Lipid Profile (Triglycerides, Total Cholesterol, LDL-C, HDL-C) | Baseline, Week 4, Week 8, Week 12, and Week 16 | Serum lipid profile including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) are measured in a central laboratory. Changes from baseline to week 16 are analyzed between groups and within subjects. |
| Secondary | Change in Serum Albumin | Baseline, Week 4, Week 8, Week 12, and Week 16 | Serum albumin (g/L) is measured at baseline, weeks 4, 8, 12, and 16. The primary analysis focuses on the change from baseline to week 16. Between-group and within-subject comparisons are performed. |
| Secondary | Change in Traditional Chinese Medicine Syndrome Score | Baseline, Week 4, Week 8, Week 12, and Week 16 | Assessment will be performed using the Traditional Chinese Medicine Syndrome Scale. The total score ranges from 22 to 88. Higher scores represent more severe TCM syndrome symptoms (worse condition). The total score is obtained by summing individual symptom-item scores. At each scheduled follow-up visit, the therapeutic efficacy index is computed as (Baseline TCM syndrome score - TCM syndrome score at the corresponding visit) / Baseline TCM syndrome score × 100%. Within-subject changes and between-group comparisons of the TCM syndrome score will be assessed from baseline to week 16. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907965
GET https://conductscience.org/api/trials/v1/NCT07907965/registered